Related Experiment Video
Updated: Jun 4, 2026
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
Evaluation of an intraperitoneal ovarian cancer syngeneic mouse model using 18F-FDG MicroPET imaging
Hye Jeong Lee1, Mohammed N Tantawy, Ki Taek Nam
1Department of Radiology and Radiological Sciences, The Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN 37232, USA. hye-jeong.lee@vanderbilt.edu
Objectives:
The objective of this study was to evaluate the syngeneic immunocompetent mouse model by using the micro-positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose (F-FDG microPET) imaging of ovarian tumor growth.
Methods:
ID8 ovarian carcinoma cells derived from C57BL/6 mice were intraperitoneally injected into female C57BL/6 mice. Mice were injected with F-FDG (7.4 MBq, intravenous injection), and microPET images were obtained 40 minutes later. Micro-computed tomographic images were also obtained immediately after microPET images for anatomical reference. F-FDG microPET images were acquired at baseline and at 4, 8, 10, and 11 weeks after tumor cell injection. The maximum standardized uptake value (SUVmax) in each time point was obtained from the images and compared to follow the tumor growth.
Results:
Physiological uptake of F-FDG was intensely found in the bladder and heart and frequently in the gastrointestinal tract. Diffused uptake of F-FDG was observed in the peritoneal cavity of all tumor-bearing mice at 4 weeks, and high focal uptakes were developed in the peritoneal cavity at 8 to 11 weeks. High focal uptakes increased over time, correlating with a progressive increase in the SUVmax of F-FDG. At 11 weeks, the SUVmax value was significantly increased (1.49 ± 0.10 at 11 weeks vs 0.29 ± 0.03 at baseline, P < 0.01). Tumors in the gut and peritoneum were confirmed by anatomical and histopathological examination.
Conclusions:
Our results demonstrate that the peritoneal tumor growth in the syngeneic ovarian cancer model can be detected by the F-FDG microPET imaging.
Insights
This study shows that 2-[fluorine-18]-fluoro-2-deoxy-d-glucose (F-FDG) microPET imaging effectively detects ovarian cancer peritoneal tumor growth in a syngeneic mouse model. The imaging technique correlated with tumor progression over time.
Area of Science:
- Oncology
- Medical Imaging
- Preclinical Research
Background:
- Ovarian cancer often presents with peritoneal metastasis.
- Developing effective imaging techniques for preclinical models is crucial for understanding tumor growth and evaluating therapies.
- Syngeneic immunocompetent mouse models are valuable for studying cancer immunology and treatment responses.
Purpose of the Study:
- To evaluate the utility of 2-[fluorine-18]-fluoro-2-deoxy-d-glucose (F-FDG) micro-positron emission tomography (microPET) imaging for monitoring ovarian tumor growth.
- To assess the syngeneic immunocompetent mouse model for ovarian cancer research using F-FDG microPET.
Main Methods:
- ID8 ovarian carcinoma cells were injected intraperitoneally into C57BL/6 mice.
- Mice received intravenous F-FDG injections, followed by microPET and micro-computed tomography imaging.
- F-FDG microPET scans were performed at multiple time points (baseline to 11 weeks) to track tumor development.
Main Results:
- Physiological F-FDG uptake was observed in the bladder, heart, and gastrointestinal tract.
- Tumor-associated F-FDG uptake in the peritoneal cavity increased progressively from 4 to 11 weeks.
- The maximum standardized uptake value (SUVmax) significantly increased over time, confirming tumor growth.
Conclusions:
- F-FDG microPET imaging is a viable method for detecting peritoneal tumor growth in a syngeneic ovarian cancer mouse model.
- This imaging approach allows for non-invasive monitoring of tumor progression in preclinical studies.
